@article{ATM31564,
author = {Wei Guo and Dahao Yang and Dengxuan Wu and Huixia Liu and Shiqun Chen and Jin Liu and Li Lei and Yong Liu and Lifen Rao and Li Zhang and The RESCIND Group},
title = {Hyperuricemia and long-term mortality in patients with acute myocardial infarction undergoing percutaneous coronary intervention},
journal = {Annals of Translational Medicine},
volume = {7},
number = {22},
year = {2019},
keywords = {},
abstract = {Background: Although serum uric acid (UA) was regarded to be involved in cardiovascular disease, the role of serum UA (SUA) as a risk factor in acute myocardial infarction (AMI) is controversial. We investigated whether hyperuricemia was linked with long-term mortality in patients with AMI who underwent percutaneous coronary intervention (PCI).
Methods: Patients with AMI who received PCI were consecutively included. The definition of preprocedural hyperuricemia was a SUA level >7 mg/dL (417 mmol/L) in males and >6 mg/dL (357 mmol/L) in females. All-cause mortality was assessed during 2.3-year median follow up period.
Results: One thousand and five patients with AMI undergoing PCI were enrolled in a single center study, 307 (30.5%) patients had hyperuricemia. After adjusting for potential confounding factors, the multivariable analysis indicated that preprocedural hyperuricemia was related to an increased risk of all-cause mortality during the 2.3-year follow-up (HR: 1.97; 95% CI: 1.11–3.49; P=0.019).
Conclusions: Preprocedural hyperuricemia, independently from chronic kidney disease (CKD), is a significant and independent predictor of long-term mortality for patients with AMI who underwent PCI.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/31564}
}